Newnow: Holding Subsidiary Aimese Zhu Monoclonal Antibody Injection Approved for Drug Clinical Trials.

The announcement from Xinnovi states that its holding subsidiary, Juishi Biotechnology, has recently received the drug clinical trial approval notification letter issued by the National Medical Products Administration for the Amisuzumab Injection, and will soon conduct clinical trials. This product is a biosimilar of the original drug Advate, and is suitable for patients with type A hemophilia. However, drug research and development has the characteristics of high investment, high risk, and long cycles, with risks such as clinical trial results not meeting expectations. In the short term, this will not have a significant impact on Juishi Biotechnology and the company's performance.